{"filing":{"accession_number":"0000879407-26-000058","cik":"0000879407","ticker":"ARWR","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"arwr-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/879407/000087940726000058/arwr-20260804.htm"},"events":[{"id":23791,"run_id":21518,"accession_number":"0000879407-26-000058","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Arrowhead Pharmaceuticals' fiscal 2026 third quarter financial results for the period ended June 30, 2026. The filing includes consolidated condensed financial information showing revenue of $75.3 million, operating loss of $170.1 million, and net loss of $194.3 million, along with detailed commentary on commercial and R\u0026D progress. The press release is furnished as Exhibit 99.1 and is the primary disclosure under Item 2.02.","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24124,"accession_number":"0000879407-26-000058","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Arrowhead Pharmaceuticals' fiscal 2026 third quarter financial results for the period ended June 30, 2026. The filing includes consolidated condensed financial information showing revenue of $75.3 million, operating loss of $170.1 million, and net loss of $194.3 million, along with detailed commentary on commercial and R\u0026D progress. The press release is furnished as Exhibit 99.1 and is the primary disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:17:32.592615+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24124,"accession_number":"0000879407-26-000058","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Arrowhead Pharmaceuticals' fiscal 2026 third quarter financial results for the period ended June 30, 2026. The filing includes consolidated condensed financial information showing revenue of $75.3 million, operating loss of $170.1 million, and net loss of $194.3 million, along with detailed commentary on commercial and R\u0026D progress. The press release is furnished as Exhibit 99.1 and is the primary disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:17:32.592615+00:00","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","filing_date":"2026-08-04"}]}